A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Okami Medical Announces First Patients Treated With The LOBO Vascular Occluder

The First Offering in the Company's Product Portfolio, LOBO-3, Recently Received 510(k) Clearance from the FDA for the Occlusion of Peripheral Arteries.

The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, one-and-done solution for the occlusion of various arterial targets without the need for multiple embolic devices.

Okami Medical advises the LOBO system combines a patented design with proprietary HDBRAIDTM technology to create a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure.  The LOBO-3 occluder is intended for use in 1.5 to 3 mm diameter vessels.

Dr. Ripal Gandhi, Interventional Radiologist, Miami Cardiac and Vascular Institute, performed the first LOBO-3 implant.  “We have successfully utilized the LOBO-3 occluder to embolize several small vessels via a microcatheter.  The device has resulted in immediate occlusion of the target vessels.  The device tracks well and deploys precisely at the desired location.  The LOBO-3 occluder is a great addition to the embolic armamentarium for the occlusion of small vessels,” said Dr. Gandhi.

“Guided by world-class physician collaborators, Okami is committed to addressing numerous challenging aspects of peripheral vascular occlusion,” said Bob Rosenbluth, Ph.D., President, and CEO of Okami Medical.  “We are very pleased with the clinical performance of the LOBO-3 occluder in the initial cases.  The device is in clinical use at key centers and we look forward to expanding our launch in 2020.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy